The analyst rating for WUXI APPTEC was raised to Overweight by Morgan Stanley due to several key factors: 1. Increased Earnings Forecast: Morgan Stanley raised its earnings forecast for 2026-30 by 0-3% based on improved gross margins. 2. Target Price Increase: The target price was increased from HKD143 to HKD143.5. 3. Strong Earnings Growth Prediction: The broker predicts a compound annual growth rate (CAGR) of 24% for WUXI APPTEC's earnings from 2024 to 2027. 4. Competitive Advantages: The firm is optimistic about WUXI APPTEC's unique CRDMO/CTDMO model and platform advantages, which position it favorably compared to domestic competitors. 5. Project Visibility: WUXI APPTEC has the largest number of early-stage projects among Chinese competitors, providing stronger visibility for medium- to long-term growth. These factors collectively contributed to the positive outlook and the Overweight rating assigned to the company.

Nomura

NULL

Buy

upgrade

2026-02-12

Reason

Nomura

Price Target

2026-02-12

upgrade

NULL

Buy

Reason

The analyst rating for WUXI APPTEC was raised to a Buy by Nomura due to a positive profit alert indicating significant growth in revenue and net profit for 4Q25, with estimates showing a 9.2% increase in revenue and a 142% increase in net profit year-over-year. Additionally, the company's anticipated revenue growth of 16% year-over-year for FY26, driven by strong performance in the chemical business, surpasses market expectations. This positive outlook led Nomura to increase the target price from HKD132.8 to HKD157.07.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 02359

Unlock Now

02359 Should I Buy

02359 Should I Buy

Should You Buy WUXI APPTEC (02359) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

Growth

Profitability

Efficiency

People Also Watch